Lexicon initiates Ph II IBS trial for LX1031

The USA's Lexicon Pharmaceuticals has initiated a Phase II trial of LX1031, its oral drug candidate for the treatment of irritable bowel  syndrome.

The trial, which began at the end of last year, is a four-week,  randomized, double-blind, placebo-controlled study to evaluate the  safety and tolerability of LX1031 and its effects on symptoms associated  with IBS. The study will include 150 patients with either  diarrhea-predominant IBS or mixed IBS. Two dose levels will be  evaluated: 250mg and 1,000mg, each administered four times daily. The  endpoints will include assessments of the effects of LX1031 on specific  symptoms associated with IBS, as well as a global assessment of adequate  relief.